Narrows 2025 revenue view to $3.15B-$3.2B from $3.125B-$3.2B, consensus $3.17B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin’s Vosoritide Study: A Potential Game-Changer for Hypochondroplasia Treatment
- BioMarin’s Vosoritide Study: A Potential Game-Changer in Pediatric Growth Disorders
- BioMarin’s Long-Term Study on BMN 270: A Potential Game Changer for Hemophilia A
- BioMarin’s Vosoritide Study: A Long-Term Hope for Hypochondroplasia
- BioMarin’s BMN 351 Study: A New Hope for Duchenne Muscular Dystrophy